Literature DB >> 2504593

Serum bactericidal activity against Enterobacteriaceae producing broad-spectrum beta-lactamases in volunteers administered ofloxacin and cefotaxime, alone or combined.

P Weber1, Y Boussougant, R Farinotti, C Carbon.   

Abstract

The activity of ofloxacin and cefotaxime, alone or combined, against four strains of Enterobacteriaceae was evaluated both in vitro and in sera from volunteers given a single infusion over 30 min of 200 mg ofloxacin or 1 g cefotaxime. The strains showed resistance or decreased susceptibility to third-generation cephalosporins. The combination was not found to be synergistic in vitro. Analysis of the bactericidal titres and killing kinetics of sera taken at the time of the peak concentration and 6 h after the infusion, respectively, confirmed the absence of synergy between the drugs against these strains.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2504593     DOI: 10.1007/bf01967472

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  9 in total

1.  Serum bactericidal rate as measure of antibiotic interactions.

Authors:  L L Briceland; M T Pasko; J M Mylotte
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

Review 2.  Microbial resistance to newer generation beta-lactam antibiotics: clinical and laboratory implications.

Authors:  C C Sanders; W E Sanders
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

3.  Bactericidal effect of ofloxacin alone and combined with fosfomycin or vancomycin against Staphylococcus aureus in vitro and in sera from volunteers.

Authors:  P Weber; Y Boussougant; F Ichou; C Dutoit; C Carbon
Journal:  J Antimicrob Chemother       Date:  1987-12       Impact factor: 5.790

4.  Dissemination of the novel plasmid-mediated beta-lactamase CTX-1, which confers resistance to broad-spectrum cephalosporins, and its inhibition by beta-lactamase inhibitors.

Authors:  M D Kitzis; D Billot-Klein; F W Goldstein; R Williamson; G Tran Van Nhieu; J Carlet; J F Acar; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

5.  Value of serum tests in combined drug therapy of endocarditis.

Authors:  T A Drake; C J Hackbarth; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

6.  Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase.

Authors:  D Sirot; J Sirot; R Labia; A Morand; P Courvalin; A Darfeuille-Michaud; R Perroux; R Cluzel
Journal:  J Antimicrob Chemother       Date:  1987-09       Impact factor: 5.790

7.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.

Authors:  H Knothe; P Shah; V Krcmery; M Antal; S Mitsuhashi
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

8.  Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae.

Authors:  C Brun-Buisson; P Legrand; A Philippon; F Montravers; M Ansquer; J Duval
Journal:  Lancet       Date:  1987-08-08       Impact factor: 79.321

9.  Microdilution transfer plate technique for determining in vitro synergy of antimicrobial agents.

Authors:  P F Dougherty; D W Yotter; T R Matthews
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

  9 in total
  3 in total

Review 1.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 2.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 3.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.